Landos Biopharma

Landos Biopharma: Lanthionine Synthetase C-Like 2 (LANCL2) is a novel therapeutic target for autoimmune diseases, including inflammatory bowel disease (IBD); Crohn’s disease (CD) and ulcerative colitis (UC). Based on extensive preclinical studies, Landos has validated a unique mechanism of action involving LANCL2 that exerts potent anti-inflammatory effects with an outstanding safety profile. Successfully raised $60MM Series B in August 2019 with Perceptive and RTW.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - South Atlantic
Clinical Stage
Phase l or ll
Disease Space
Autoimmune, Gastrointestinal, Metabolic Disorders
Listing
Public, USA
Market Cap
100MM - 500MM
Website:
Profiles:
Address:
1800 Kraft Drive SW
Suite 216
Blacksburg, VA 24060
United States

Company Participants at Solebury Trout Corporate Access 1x1 Calls - Week of April 13

  • Josep Bassaganya-Riera, President & CEO

Lead Programs

BT-11

Indication Phase
LANCL2 2
LANCL2 1

NX-13

Indication Phase
NLRX1 IND
NLRX1 IND

BT-104

Indication Phase
LANCL2 Pre-clinical
LANCL2 Pre-clinical

Top 10 Holders of Landos Biopharma, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
RTW Investments LP 12.51 4,900,722 55.23 Stakes 2/8/21
JPMorgan Investment Management, Inc. 0.63 245,176 2.76 Funds 2/28/21
The Vanguard Group, Inc. 0.15 59,384 0.67 Funds 2/28/21
Geode Capital Management LLC 0.05 18,662 0.21 Funds 2/28/21
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.